[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100453427":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":40,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Herlev and Gentofte Hospital","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":13,"zip":14,"country":15,"countryCode":16,"cosmosGeoPoint":17,"geoPoint":22,"contacts":23},"Herlev & Gentofte Hospital","RECRUITING","Herlev","Copenhagen","2700","Denmark","DK",{"type":18,"coordinates":19},"Point",[20,21],12.43998,55.72366,{"lat":21,"lon":20},[24,29,33,36,38],{"name":25,"role":26,"phone":27,"phoneExt":7,"email":28},"Troels D Christensen, MD","CONTACT","+4538681381","troels.dreier.christensen.01@regionh.dk",{"name":30,"role":26,"phone":31,"phoneExt":7,"email":32},"Julia S Johansen, D.M.Sc. MD","+4538689241","Julia.Sidenius.Johansen@regionh.dk",{"name":34,"role":35,"phone":7,"phoneExt":7,"email":7},"Ole Larsen, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":25,"role":37,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"name":39,"role":37,"phone":7,"phoneExt":7,"email":7},"Julia S Johansen, MD, D.M.Sc.",{"type":35,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Troels Dreier Christensen","Principal Investigator","100453427","identification-of-new-biomarkers-for-patients-with-cholangiocarcinoma-and-gallbladder-cancer-100453427",false,"NCT05184400","Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer","Identification of New Biomarkers for Patients With Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - do They Provide New Information Regarding Diagnosis, Treatment Efficacy, Side Effects, or Prognosis?","CHOCA","Inclusion Criteria:\n\n* Histological or cytological diagnosis of BTC\n* Patients referred for treatment of BTC\n* Signed informed consent\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":54,"type":55},500,"ESTIMATED","OBSERVATIONAL","No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.",[59,60,61],"Biliary Tract Cancer","Cholangiocarcinoma","Gallbladder Cancer",[63,64,65,66,67],"Prospective observational open cohort study","Biomarkers","Diagnostics","Prognostics","Prediction of treatment efficacy","2021-12-21",{"date":70,"type":71},"2022-01-11","ACTUAL",{"date":73,"type":71},"2015-01-01",{"date":75,"type":55},"2030-12-31",{"name":5,"class":6},1]